Sep 14 2009
DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher’s new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.
DSG’s eCaseLink™ makes it possible to merge and analyze a highly complex array of widely varied data across a large patient base. Cipher is using DSG’s integrated data management services for all aspects of database design, usage, freeze, lock and archiving at 50 sites throughout the U.S. and Canada with 800 patients estimated to complete the study over an anticipated 18 month period.
“As we move forward with our clinical trial process it is essential that we have the latest in EDC and data management technology that reduces overall trial costs and improves data quality,” said Jason A. Gross, Pharm.D., Vice President of Scientific Affairs, Cipher Pharmaceuticals. “DSG’s EDC offering in combination with integrated data management helps us meet our objectives to bring the latest therapies to market.”
“DSG is proud to be supporting Cipher Pharmaceuticals through its critical Phase 3 study,” said Tony Varano, CEO, DSG, Inc. “We are confident that our integrated approach to EDC and data management will reap tangible benefits in controlling costs and ensuring study success at Cipher, putting a new face on a proven treatment for severe acne.”
www.cipherpharma.com
Link between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disorders